Anaxomics is a biotech company focused in Bioinformatics. We implement Systems Biology through our proprietary technology, the Therapeutic Performance Mapping System (TPMS), a top-down approach which molecularly models human pathophysiology in silico through the use of artificial intelligence, providing biomedical big data integration. Our technology integrates, in a map of the human functional interactome, the molecular information available in the scientific literature and the experimental information generated by each customer or collaborator, with special emphasis in the clinical translation of results. This allows overcoming challenges in any of the following areas:
- Academic and discovery-stage research
- Pre-clinical research
- Clinical research
- Nutraceuticals, cosmetics and veterinary
- High throughput data analysis
- Biomedical investment
We exploit these molecular models of human pathophysiology through the use of different artificial intelligence techniques, which allow us for the performance of different in silico analyses:
- Mechanism of action identification
- Drug repositioning
- Biomarker discovery
- High-throughput data analysis
- Molecular target and off-target discovery
- Therapeutic target discovery
- Treatment efficacy & safety benchmarking
- Drug head-to-head comparison
- Patient stratification
- Clinical trial molecular design & analysis
- ...
Founded in 2007 and headquartered in Barcelona (Spain), and thanks to a seasoned team of skilled experts, Anaxomics offers cutting-edge systems biology approaches in combination with a strong expertise in the fields of drug development, clinical research and biotechnology. Moreover, we are constantly working to refine our current tools and develop new services to better meet our clients’ and collaborators’ needs. We invite you to learn more about our company in the following sections: